<DOC>
	<DOC>NCT01277328</DOC>
	<brief_summary>This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients &gt;/=18 years of age Patients with rheumatoid arthritis eligible for RoActemra Hypersensitivity to RoActemra Active, severe infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>